Skip to main content
The U.S. Department of Veterans Affairs (VA) announced that its health care professionals will now be able to offer veterans with treatment-resistant depression therapy with the newly approved esketamine nasal spray drug, Spravato. Spravato will be made available to veterans based on clinical assessments conducted by VA medical professionals. Spravato is a Food and Drug Administration (FDA)-approved prescription treatment that is thought to work differently than currently approved therapies for major depressive disorder (MDD) and treatment- resistant depression (TRD). People who are currently struggling with MDD are considered to have TRD if they have not responded adequately . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase A Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!


Support Request

Need help now?

Call our toll-free phone number 877-350-6463